CAM
DNA icon

Concorde Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Concorde Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-504
Closed -$167K – 164
2021
Q4 		$167K Buy
504
+35
+7% +$16.6K 0.1% 162
2021
Q3 		$217K Buy
+469
New +$228K 0.13% 173

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
SIG
Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Concorde Asset Management's DNA Position: Q1 2022 in Review

Concorde Asset Management sold out of Ginkgo Bioworks (DNA) in Q1 2022, closing a stake of 504 shares — an estimated $167K sold.

Concorde Asset Management first reported a position in DNA in Q3 2021 and held it in 2 quarters. The position peaked at $217K in Q3 2021. 190 funds tracked by Wall St. Rank hold DNA as of Q1 2022.

  • Concorde Asset Management reported no remaining Ginkgo Bioworks position as of Q1 2022 after selling out during the quarter.
  • Concorde Asset Management sold 504 Ginkgo Bioworks shares in Q1 2022, an estimated $167K.
  • Concorde Asset Management first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 2 quarters.
  • Concorde Asset Management's Ginkgo Bioworks position peaked at $217K in Q3 2021.
  • 190 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2022.

Based on Concorde Asset Management's 13F filing for Q1 2022, filed 22 Apr 2022.